±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À², ±Ô¸ð, µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : À¯Çüº°, Á¦Ç°º°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2023-2032³â)
Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032
»óǰÄÚµå : 1388188
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2023³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 115 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,082,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,513,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,945,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris market researchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö 29¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

±¸°­°ÇÁ¶Áõ Á¦Ç°¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥, Áï ±¸°­°ÇÁ¶Áõ Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ´Â ºñ¿ëÀÇ ÀϺΰ¡ º¸ÇèÀ̳ª ÀǷẸÇè¿¡¼­ º¸ÀåµÇ±â ¶§¹®¿¡ ´õ ½±°í Àú·ÅÇÑ ºñ¿ëÀ¸·Î ÀÌ·¯ÇÑ Á¦Ç°À» ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. À̴ ȯÀÚµéÀÌ Ä¡·á¸¦ ¹Þµµ·Ï À¯µµÇÏ°í ±Ã±ØÀûÀ¸·Î ±¸°­°ÇÁ¶Áõ °ü·Ã Á¦Ç° ¹× ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù. ±¸°­°ÇÁ¶ÁõÀº Á¾Á¾ ¼î±×·» ÁõÈıº, ´ç´¢º´, °íÇ÷¾Ð, ÆÄŲ½¼º´°ú °°Àº ±âÀúÁúȯÀÇ Áõ»óÀ̳ª ºÎÀÛ¿ëÀ¸·Î ³ªÅ¸³ª´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ ÀÇ·áÁø°ú ÀϹÝÀεéÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ´õ ¸¹Àº »ç·Ê°¡ Áø´Ü ¹× Ä¡·áµÇ°í ÀÖ½À´Ï´Ù. ÀÇ·áÁøÀº ÀÌ·¯ÇÑ ±âÀúÁúȯÀ» °¡Áø ȯÀÚÀÇ ±¸°­°ÇÁ¶Áõ Áõ»óÀ» ÆÄ¾ÇÇϰí Ä¡·áÇÒ °¡´É¼ºÀÌ ³ô¾ÆÁö±â ¶§¹®ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, Colgate-Palmolive Company¿Í Sjogren Syndrome Foundation of America¿Í °°Àº ±â°ü¿¡¼­ Á¦°øÇÏ´Â Åë°è´Â ¹Ì±¹ ³» ±¸°­°ÇÁ¶Áõ ¹× °ü·Ã ÁúȯÀÇ À¯º´·üÀ» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼öÄ¡´Â È¿°úÀûÀÎ Ä¡·á¹ýÀÇ Çʿ伺°ú ´õ Å« °Ç°­ ¹®Á¦ÀÇ Áõ»óÀ¸·Î¼­ ±¸°­°ÇÁ¶ÁõÀ» ´Ù·ç´Â °ÍÀÇ Á߿伺À» °­Á¶ÇÕ´Ï´Ù.

¼î±×·» ÁõÈıº Àç´ÜÀº ¼î±×·» ÁõÈıº¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ°í ±¸°­°ÇÁ¶ÁõÀ» ¾Î°í ÀÖ´Â ¼î±×·» ÁõÈıº ȯÀÚµéÀ» µ½±â À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ Àç´ÜÀº ¹Ì±¹°ú ij³ª´Ù¿¡¼­ ÀÌ ÀÚ°¡¸é¿ªÁúȯÀ» ¾Î°í Àִ ȯÀÚµéÀ» Áö¿øÇϰí, 2017³â±îÁö ¼î±×·» ÁõÈıº Áø´Ü ±â°£À» 2.5³â À̳»·Î ´ÜÃàÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â '5-Year Breakthrough Goal'À» µµÀÔÇØ ÀÎ½Ä °³¼± ÇÁ·Î±×·¥À» ÁøÇàÇϰí ÀÖ½À´Ï´Ù. À̸¦ ÅëÇØ ¼î±×·» ÁõÈıºÀÇ Áø´Ü°ú Ä¡·á ¼Óµµ¸¦ ³ôÀ̰í, Á¾ÇÕÀûÀÎ Ä¡·á °èȹÀÇ ÀÏȯÀ¸·Î ±¸°­°ÇÁ¶Áõ ¹®Á¦¸¦ ÇØ°áÇϰíÀÚ Çß½À´Ï´Ù.

¶ÇÇÑ, ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ½ºÅ¸Æ®¾÷ Àμö¿Í ÀÎ½Ä Á¦°í ÇÁ·Î±×·¥ ½ÇÇàÀÇ Á߿伺À» ÀνÄÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¿À¶óÁ©(Orajel)Àº ¾ÆÀÌÅ©·Î½Ì(iCrossing)°ú ÇÔ²² Ä·ÆäÀÎÀ» ½ÃÀÛÇß½À´Ï´Ù. ÀÌ Ä·ÆäÀÎÀÇ ¸ñÀûÀº ±¸°­°ÇÁ¶Áõ°ú °°Àº ¹®Á¦ ÇØ°áÀ» Æ÷ÇÔÇÑ ±¸°­ °ü¸®ÀÇ Á߿伺¿¡ ´ëÇØ ºÎ¸ð¸¦ ±³À°ÇÏ´Â °ÍÀ̾ú½À´Ï´Ù. ±¸°­ °Ç°­ ¹× ±¸°­°ÇÁ¶Áõ°ú °°Àº Áõ»ó¿¡ ´ëÇØ ´ëÁßÀ» ±³À°ÇÔÀ¸·Î½á, ÀÌ·¯ÇÑ ³ë·ÂÀº ±¸°­°ÇÁ¶Áõ°ú ±× Ä¡·á¹ý¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀÌ´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

OTC ÀǾàǰ ºÎ¹®Àº ½±°Ô ±¸ÇÒ ¼ö ÀÖ°í, °¡°ÝÀÌ Àú·ÅÇϸç, À¯È¿À²ÀÌ ³ô±â ¶§¹®¿¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù.

Ä¡¾à ºÎ¹®Àº Çʼö Ÿ¾× ¼ººÐÀÎ Ä®½·°ú Àλ꿰À» ȸº¹½ÃÄÑ Å¸¾× ÀÚ±ØÁ¦¸¦ °³¼±ÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ´õ È¿À²ÀûÀ̱⠶§¹®¿¡ ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì Áö¿ªÀÌ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇϰí Àִµ¥, ÀÌ´Â ÁÖ·Î ±¸°­°ÇÁ¶ÁõÀÇ ÆóÇØ¿¡ ´ëÇÑ È¯ÀÚµéÀÇ Àνİú ¹ß´ÞµÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇÑ È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ±âÀÎÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå¿¡ °üÇÑ ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Á¦Ç°º°

Á¦6Àå ¼¼°èÀÇ ±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, À¯Çüº°

Á¦7Àå ¼¼°èÀÇ ±¸°­°ÇÁ¶Áõ Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°

Á¦8Àå °æÀï »óȲ

Á¦9Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global xerostomia therapeutics market size is expected to reach USD 2.94 billion by 2032, according to a new study by Polaris market research. The report "Xerostomia Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Type (OTC, Prescription), By Product, By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Favorable reimbursement policies for xerostomia products. This means that individuals who require treatment for xerostomia can access these products more easily and at reduced costs, as a portion of their expenses is covered by insurance or healthcare plans. This encourages patients to seek treatment, ultimately driving the demand for xerostomia-related products and medications. Xerostomia is often a symptom or side effect of underlying conditions such as Sjogren's syndrome, diabetes, hypertension, and Parkinson's disease.

As awareness of these diseases increases among both healthcare professionals and the general population, more cases are being diagnosed and treated. This, in turn, has a positive impact on the demand for xerostomia treatments, as healthcare providers are more likely to identify and address dry mouth symptoms in patients with these underlying conditions. For instance, statistics provided by organizations like Colgate-Palmolive Company and the Sjogren Syndrome Foundation of America highlight the prevalence of xerostomia and related diseases in the United States. These figures underscore the need for effective treatments and the importance of addressing xerostomia as a symptom of larger health concerns.

Sjogren Syndrome Foundation of America's efforts to create awareness and support patients affected by Sjogren's syndrome, a condition often accompanied by xerostomia. The foundation conducts awareness programs and aids individuals suffering from this autoimmune disorder in both the United States & Canada. Introduced "5-Year Breakthrough Goal" with the objective of reducing the time it takes to diagnose the condition to less than 2.5 years by 2017. By doing so, they aimed to expedite the diagnosis and treatment of Sjogren's syndrome, which often includes addressing the issue of xerostomia as part of the comprehensive care plan.

Additionally, major players in the market recognize the importance of both acquiring emerging companies and conducting awareness programs. For instance, Orajel initiated a campaign in collaboration with iCrossing; the goal of this campaign was to educate parents about the significance of oral care, which includes addressing issues like xerostomia. By educating the public about oral health and conditions like dry mouth, these initiatives contribute to increasing awareness about xerostomia and its treatment options.

Xerostomia Therapeutics Market Report Highlights

The OTC segment dominated the market, as they are easily available, affordable, and have a higher efficacy rate

The dentifrices segment will grow rapidly, as they are more efficient as they focus on improving the salivary stimulants by restoring essential salivary components, Calcium, and phosphate

North America held the largest share, primarily due to patient awareness regarding the ill effects of xerostomia, effective treatment options via its well-developed medical infrastructure

The key market players include GlaxoSmithKline, Hikma Pharmaceuticals, Pendopharm, Sun Pharma, Lupin Pharmaceuticals, and Pfizer

Polaris market research has segmented the xerostomia therapeutics market report based on type, product, and region:

Xerostomia Therapeutics, Type Outlook (Revenue - USD Billion, 2023 - 2032)

Xerostomia Therapeutics, Product Outlook (Revenue - USD Billion, 2023 - 2032)

Xerostomia Therapeutics, Regional Outlook (Revenue - USD Billion, 2023 - 2032)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Xerostomia Therapeutics Market Insights

5. Global Xerostomia Therapeutics Market, by Product

6. Global Xerostomia Therapeutics Market, by Type

7. Global Xerostomia Therapeutics Market, by Geography

8. Competitive Landscape

9. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â